Epirus Biopharmaceuticals Stock Beta
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
EPIRUS Biopharmaceuticals fundamentals help investors to digest information that contributes to EPIRUS Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of EPIRUS Pink Sheet. The fundamental analysis module provides a way to measure EPIRUS Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EPIRUS Biopharmaceutica pink sheet.
EPIRUS |
EPIRUS Biopharmaceuticals Company Beta Analysis
EPIRUS Biopharmaceutica's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current EPIRUS Biopharmaceutica Beta | 4.28 |
Most of EPIRUS Biopharmaceutica's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EPIRUS Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, EPIRUS Biopharmaceuticals has a Beta of 4.2832. This is 398.05% higher than that of the Biotechnology sector and 208.14% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
EPIRUS Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EPIRUS Biopharmaceutica's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of EPIRUS Biopharmaceutica could also be used in its relative valuation, which is a method of valuing EPIRUS Biopharmaceutica by comparing valuation metrics of similar companies.EPIRUS Biopharmaceutica is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, EPIRUS Biopharmaceutica will likely underperform.
EPIRUS Fundamentals
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (37.45) % | |||
| Current Valuation | (6 M) | |||
| Shares Outstanding | 26.18 M | |||
| Number Of Shares Shorted | 252.54 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 701 K | |||
| Gross Profit | 576 K | |||
| EBITDA | (54.6 M) | |||
| Net Income | (52.19 M) | |||
| Cash And Equivalents | 20.86 M | |||
| Cash Per Share | 0.80 X | |||
| Total Debt | 14.85 M | |||
| Debt To Equity | 0.57 % | |||
| Current Ratio | 0.79 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (46.58 M) | |||
| Short Ratio | 0.07 X | |||
| Earnings Per Share | (2.52) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 73 | |||
| Beta | 4.28 | |||
| Market Capitalization | 157 | |||
| Total Asset | 72.26 M | |||
| Retained Earnings | (155.03 M) | |||
| Working Capital | (6.93 M) | |||
| Current Asset | 25.69 M | |||
| Current Liabilities | 32.63 M | |||
| Z Score | -2.8 | |||
| Net Asset | 72.26 M |
About EPIRUS Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EPIRUS Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EPIRUS Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EPIRUS Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with EPIRUS Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EPIRUS Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to EPIRUS Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EPIRUS Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EPIRUS Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EPIRUS Biopharmaceuticals to buy it.
The correlation of EPIRUS Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EPIRUS Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EPIRUS Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EPIRUS Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |